This activity is supported by an independent educational grant from Kyowa Kirin. This online education program has been designed solely for healthcare professionals in the USA. The information in this program is not suitable for any other country.

Join leading experts Dr Alison Moskowitz, Dr Steven Horwitz, and Dr Basem William for this accredited virtual webinar. This is a 60-minute live-virtual summit designed to address the real-world clinical and operational challenges of diagnosing, assessing, and managing mycosis fungoides (MF) and Sézary syndrome (SS) across the patient journey. Moving beyond basic diagnostic criteria, this case-based program emphasizes practical clinical decision-making, multi-compartment disease assessment, and multidisciplinary care coordination to support timely, individualized treatment strategies across the cutaneous T-cell lymphoma (CTCL) continuum.

Participants will evaluate evidence-based diagnostic algorithms and repeat biopsy strategies to mitigate diagnostic delays, while mastering Tumor, Node, Metastasis, Blood (TNMB) staging principles to assess disease burden across skin, blood, lymph node, and visceral compartments.

Session Highlights

• Early Recognition & Diagnostic Strategies: Identify diverse clinical and histopathological presentations mimicking common inflammatory skin disorders, apply evidence-based diagnostic algorithms, and utilize repeat biopsy strategies to mitigate diagnostic delay.
• Multi-Compartment Assessment & Staging: Master TNMB staging principles and evaluate disease burden across skin, blood, lymph node, and visceral compartments.
• Progression Recognition: Differentiate subtle indicators of disease progression from inflammatory flares, treatment-related effects, and fluctuating symptoms.
• Individualized Treatment Planning: Incorporate emerging efficacy and safety evidence for systemic therapies into treatment selection and determine appropriate timing for escalation to systemic treatment options.
• Multidisciplinary Pathways: Establish coordinated referral pathways and clarify roles across dermatology, hematology/oncology, pathology, nursing, and CTCL specialists.

Who Should Watch

This program is designed for U.S.-based healthcare professionals involved in the recognition, diagnosis, assessment, referral, and management of patients with MF and SS, including:

➔ Dermatologists

➔ Hematologist/oncologists

➔ Dermatology-focused nurse practitioners (NPs) and physician associates/physician assistants (PAs)

➔ Oncology-focused NPs and physician associates/PAs

➔ Other healthcare professionals involved in CTCL diagnosis, referral, assessment, and management

Faculty

Dr Alison Moskowitz, MD, is an Associate Attending within the Lymphoma service at Memorial Sloan Kettering Cancer Center, with a focus on treating patients with Hodgkin lymphoma, systemic T-cell lymphoma, and CTCL. She is a clinical investigator, dedicated to developing novel treatment approaches for patients with relapsed or refractory Hodgkin lymphoma and identifying factors predictive of response to therapy and overall outcomes.

Dr Steven Horwitz, MD, is an Attending Physician in the Department of Medicine at Memorial Hospital for Cancer and Allied Diseases and a Member at Memorial Sloan Kettering Cancer Center in New York City. Much of his current research is dedicated to investigating targeted or immunotherapeutic approaches to try to identify better, and often less toxic treatments for individuals with T-cell lymphomas. His research also focuses on better understanding mechanisms of response and resistance to novel drugs in T-cell lymphoma to help provide individualized treatments in the future. Dr. Horwitz participates in several national, and international committees and consortiums dedicated to the understanding and advancement of treatment for T-cell lymphoma. Since 2017 he has been the Chair of the NCCN panel on Guidelines for Treatment of T-Cell/Primary Cutaneous B-Cell Lymphomas and member of the Lymphoma Research Foundation Scientific Advisory Board.

Dr Basem William, MD, MRCP(UK), FACP, is a hematologist/oncologist and a clinical/translational investigator with an internationally-recognized expertise in hematological malignancies, lymphoma, T-cell lymphomas, cutaneous lymphoma, drug development, blood and bone marrow transplantation and cellular therapy. Dr William is a clinical inspector for the Foundation for the Accreditation of Cellular Therapy (FACT) and has been a PI/co-investigator/site PI on over 100 clinical trials in hematological malignancies and cell therapy.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Alison Moskowitz, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for Affimed, AstraZeneca, Bio Ascend, Imbrium Therapeutics L.P./Purdue, Janpix Ltd., Merck, Pfizer, Seagen, Seattle Genetics, Takeda, and Tessa Therapeutics; Research Support from ADC Therapeutics, BeiGene, Bristol Myers Squibb, Incyte, Merck, Miragen, Seattle Genetics, and Secura Bio.

Steven Horwitz, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for BMS, Click or Electra, Corvus, Daiichi Sankyo, DrenBio, J&J Medicine/Janssen Research & Development, Kyowa Hakko Kirin, March Bio, ONO Pharmaceuticals, Pfizer, SecuraBio, Sobi Inc., and Takeda; Research Support from Corvus, Crispr Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, March Bio, SecuraBio, Takeda, and Treeline

Basem William, MD, MRCP(UK), FACP, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory board for ADC Therapeutics, BMS, Genmab, Guideline Global, Incyte, Kite, Pfizer, PPD, and Tempus; Consultant for ADC Therapeutics, BMS, Genmab, Guideline Global, Incyte, Kite, Pfizer, PPD, and Tempus; Speaker's Bureau for Incyte, Kyowa Kirin, and Natera.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 30, 2026. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.

Fee Information

There is no fee for this educational activity.